title: Advancement in integrin facilitated drug delivery.
abstract: The research of integrin-targeted anticancer agents has recorded important advancements in ingenious design of delivery systems, based either on the prodrug approach, or on nanoparticle carriers, but for now, none of these has reached a clinical stage of development. Past work in this area has been extensively reviewed by us and others. Thus, the purpose and scope of the present review is to survey the advancement reported in the last 3years, with focus on innovative delivery systems that appear to afford openings for future developments. These systems exploit the labelling with conventional and novel integrin ligands for targeting the interface of cancer cells and of endothelial cells involved in cancer angiogenesis, with the proteins of the extracellular matrix, in the circulation, in tissues, and in tumour stroma, as the site of progression and metastatic evolution of the disease. Furthermore, these systems implement the expertise in the development of nanomedicines to the purpose of achieving preferential biodistribution and uptake in cancer tissues, internalisation in cancer cells, and release of the transported drugs at intracellular sites. The assessment of the value of controlling these factors, and their combination, for future developments requires support of biological testing in appropriate mechanistic models, but also imperatively demand confirmation in therapeutically relevant in vivo models for biodistribution, efficacy, and lack of off-target effects. Thus, among many studies, we have tried to point out the results supported by relevant in vivo studies, and we have emphasised in specific sections those addressing the medical needs of drug delivery to brain tumours, as well as the delivery of oligonucleotides modulating gene-dependent pathological mechanism. The latter could constitute the basis of a promising third branch in the therapeutic armamentarium against cancer, in addition to antibody-based agents and to cytotoxic agents.
authors.affiliation: Istituto di Scienze e Tecnologie Molecolari (ISTM), CNR, Via C. Golgi 19, I-20133 Milan, Italy. Electronic address: daniela.arosio@istm.cnr.it.
authors.forename: Daniela
authors.initials: D
authors.lastname: Arosio
authors.affiliation: Università degli Studi di Milano, Dipartimento di Chimica, Via C. Golgi 19, I-20133 Milan, Italy. Electronic address: cesare.casagrande@tin.it.
authors.forename: Cesare
authors.initials: C
authors.lastname: Casagrande
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D057846:Cell-Penetrating Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015316:Genetic Therapy; D006801:Humans; D016023:Integrins / Q000235:genetics / Q000378:metabolism*; D053758:Nanoparticles / Q000008:administration & dosage / Q000627:therapeutic use; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D011355:Prodrugs / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D057846:Cell-Penetrating Peptides; D016023:Integrins; D011355:Prodrugs
keywords: Cancer; Drug delivery; ECM proteins; Integrins; Nanoparticles; Peptidomimetics; RGD